Ignite Creation Date:
2025-12-24 @ 9:59 PM
Ignite Modification Date:
2026-03-27 @ 5:23 PM
Study NCT ID:
NCT00988832
Status:
COMPLETED
Last Update Posted:
2015-09-02
First Post:
2009-10-01
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Study Overview
Official Title:
A UK Retrospective Audit of Patients With Crohn's Disease Treated With Infliximab
Status:
COMPLETED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to quantify how infliximab therapy is being used in the UK and the consequent impact on health care resources, which will help to inform budget holders and payers on the costs associated with the treatment of Crohn's Disease.
Detailed Description:
All interested hospital physicians across the UK who prescribe infliximab as part of their treatment of Crohn's Disease patients. will be included. It is assumed that the physician population will consist primarily of gastroenterologists, though general physicians (hospital-based) with an interest in Crohn's Disease may also be included.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: